Breaking News

Omni Bio Appoints Development Officer

May 1, 2014

Forrest brings 25 years of industry experience

Dr. Bruce D. Forrest has been appointed chief development officer at Omni Bio Pharmaceutical, Inc. Dr. Forrest currently serves as president of B D Forrest & Co., Inc., a pharma/biopharma consulting firm that provides scientific strategy and business development support, and has worked with Omni Bio during the past year. 
 
In his expanded role, he will oversee the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule for the potential treatment of type 1 diabetes, graft versus host disease and various inflammatory conditions. He will also provide leadership for the cell line optimization and product manufacturing partnership with Gallus BioPharmaceuticals, Inc. 
 
Dr. Forrest has more than 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. Dr. Forrest was previously senior vice president in Vaccines R&D at Wyeth Pharmaceuticals, where he was responsible for clinical and development activities for all late phase programs. He also served as head of Wyeth's R&D organization in Japan and held various clinical research roles at Chiron Corp. and United Biomedical, Inc. 
 
Dr. Bruce E. Schneider, chief executive officer of Omni Bio, said, "We are extremely pleased to have Dr. Forrest serve in this role for Omni Bio. His background as an immunologist and his proven track record in managing both non-clinical and clinical R&D functions will be enormously helpful to us as we pursue the ongoing development of recombinant AAT."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks